General Dynamics Corporation vs GeneDx Holdings Corp — how do they compare? General Dynamics Corporation trades at $334 (market cap $89.26B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: General Dynamics Corporation is far larger — about 44.2× GeneDx Holdings Corp's market cap, and General Dynamics Corporation pays a 1.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and GeneDx Holdings Corp for 19 Days on average.
| GD | WGS | |
|---|---|---|
Market Cap | $89.26B | $2.02B |
Volume | 1,496,273 | 734,640 |
Sector | Industrials | Health |
52-Week High | $395.97 | $167.51 |
52-Week Low | $312.53 | $34.51 |
Typical Hold Time | 85 Days | 19 Days |
Enterprise Value | $94.40B | $2.05B |
Dividend Yield | 1.93% | — |
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.27, up 1.42% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 8.18% net margins and 17.8% ROE. Recent defense spending trends and analyst consensus of $420.57 price target suggest upside potential despite current technical weakness.
GD presents a compelling value opportunity with consistent earnings beats and strong defense sector tailwinds. Key risks include defense budget volatility and competitive pressures, but the company's $1.59 dividend and improving cash flow trends support the bullish analyst outlook. The stock's current discount to consensus target offers potential for appreciation.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →